NEW YORK, March 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Geron investors who were adversely affected by alleged securities fraud between June 7, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/geron-corporation-lawsuit-submission ...

Geron Corp (NASDAQ: GERN ) is a venerable, long-in-development-hell biotech working on the commercialization and development of the lone telomerase inhibitor approved for any indication. The year 2024 saw the first sales of their agent Rytelo in the space of lower-riskI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do y ...

NEW YORK, March 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-02563, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Geron securities between February 28, 2024 and February 25, ...

Core Viewpoint - A class action lawsuit has been filed against Geron Corporation for alleged violations of federal securities laws, specifically regarding misleading statements about its revenue outlook and growth potential [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Geron provided false and misleading information to investors, creating an overly optimistic view of the projected revenue and growth related to the launch of Rytelo [2]. - It is alleged that Geron did not disclose that Rytelo lacked necessary patient awareness, which hindered the company's ability to meet the claimed significant unmet need for the drug [2]. Group 2: Investor Participation - Shareholders who purchased Geron's securities between June 7, 2024, and February 25, 2025, are encouraged to contact the DJS Law Group to participate in the class action lawsuit before May 12, 2025 [1][3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Geron Corporation securities during the specified Class Period, indicating potential legal issues for the company related to misleading statements about its revenue outlook and product performance [1][5]. Group 1: Class Action Details - The class action is filed for securities purchased between June 7, 2024, and February 25, 2025, and investors may be entitled to compensation without upfront costs through a contingency fee arrangement [1][2]. - Interested parties can join the class action by contacting Rosen Law Firm, with a deadline to serve as lead plaintiff set for May 12, 2025 [3][6]. Group 2: Allegations Against Geron Corporation - The lawsuit alleges that Geron Corporation made false and misleading statements regarding its product Rytelo, creating an inaccurate perception of its market potential and revenue growth while downplaying risks associated with seasonality and competition [5]. - The claims suggest that the actual market performance of Rytelo was significantly below expectations, with challenges in market penetration and competition impacting patient starts more than previously indicated [5].

Core Insights - A class action has been filed against Geron Corporation on behalf of investors who acquired its securities between June 7, 2024, and February 25, 2025, due to alleged misleading information regarding the launch and growth potential of its product Rytelo [1][2]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancer treatment, with its primary product being a telomerase inhibitor named imetelstat, marketed as Rytelo [1]. Allegations - The complaint claims that Geron misled investors by presenting overly optimistic reports about Rytelo's launch success and growth potential, failing to disclose significant factors such as seasonality, competition, and the burden of monitoring that affected patient starts [2]. - It is alleged that Rytelo lacked sufficient market awareness, hindering Geron's ability to meet the significant unmet need for the drug, especially among first-line patients and those outside academic settings [2]. Financial Impact - On February 26, 2025, Geron announced its fourth-quarter financial results for fiscal 2024, revealing that Rytelo's growth had stagnated. The company attributed this to seasonality, competition, lack of awareness, and monitoring requirements [3]. - Following this announcement, Geron's stock price plummeted from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [3].

Core Viewpoint - Geron Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the performance and market potential of its primary product, Rytelo [1][3]. Group 1: Class Action Details - The class action lawsuit, titled Dabestani v. Geron Corporation, allows purchasers of Geron securities from June 7, 2024, to February 25, 2025, to seek appointment as lead plaintiff by May 12, 2025 [1][5]. - The lawsuit alleges that Geron made false statements about its revenue outlook and growth potential, downplaying risks associated with seasonality and competition [3][4]. - Geron's primary product, Rytelo, is a telomerase inhibitor, which has reportedly struggled to gain market awareness and penetration, impacting its sales performance [2][3]. Group 2: Financial Impact - On February 26, 2025, Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, and lack of market awareness, leading to a stock price decline of over 32% [4]. - The lawsuit claims that the optimistic projections made by Geron were not reflective of the actual market conditions and challenges faced by the product [3][4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit, noted for its significant recoveries in securities fraud cases, including over $2.5 billion in 2024 alone [6]. - The firm has a strong track record in securities class action recoveries, having secured the largest recovery in history at $7.2 billion in the Enron case [6].

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Geron Corporation ("Geron" or the "Company") (NASDAQ:GERN). The investigation concerns whether Geron and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On February 26, 2025, Geron announced its financial results for the fourth year and full year 2024. During a related earnings ...

NEW YORK, Feb. 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Geron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On February 26, 2025, Geron ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporat ...